Dr. Benjamin L. Kitchens, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at San Antonio (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 285
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of Texas Medical School at San Antonio
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license Q9404 (first issued 2016; active) -
Internal Medicine Physician
TX license Q9404 (first issued 2016; active) -
Medical Oncology Physician
TX license Q0404 (first issued 2014; active) -
Student in an Organized Health Care Education/Training Program
TX license BP10047479
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
- Baylor Scott and White Medical Center Lake Pointe Rowlett, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 285
- Services billed
- 39,354
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 6,000 | 23 |
| Injection, fosaprepitant, 1 mg | 4,200 | 25 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,509 | 29 |
| Injection, paclitaxel, 1 mg | 1,784 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 775 | 69 |
| Injection, granisetron hydrochloride, 100 mcg | 370 | 35 |
| Injection, palonosetron hcl, 25 mcg | 370 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 368 | 67 |
| Blood test, comprehensive group of blood chemicals | 350 | 63 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 306 | 63 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Dallas, TX | 58 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 54 |
| Ondansetron Odt (ondansetron) Other prescribers in Dallas, TX | 43 |
| Potassium Chloride Other prescribers in Dallas, TX | 33 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Dallas, TX | 26 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Dallas, TX | 25 |
| Pantoprazole Sodium Other prescribers in Dallas, TX | 24 |
| Tramadol Hcl Other prescribers in Dallas, TX | 23 |
| Oxycodone Hcl Other prescribers in Dallas, TX | 23 |
| Gabapentin Other prescribers in Dallas, TX | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 129 payments worth $84,261 in total to this clinician.
| Astellas Pharma US Inc | $34,408 |
|---|---|
| Incyte Corporation | $24,716 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14,533 |
| Jazz Pharmaceuticals Inc. | $8,323 |
| AstraZeneca Pharmaceuticals LP | $1,258 |
| Astellas Pharma Global Development | $216 |
| AbbVie Inc. | $165 |
| Genentech, Inc. | $86.98 |
| Compensation for services other than consulting (speaking, faculty) | $62,166 |
|---|---|
| Travel and Lodging | $11,434 |
| Consulting Fee | $7,344 |
| Food and Beverage | $3,318 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Aug 18, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Incyte Corporation Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $3,655 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · ONCOLOGY | $3,570 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · ONCOLOGY | $3,570 |
| Incyte Corporation Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $3,440 |
| Jazz Pharmaceuticals Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $3,354 |
All 59 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma Global Development Dec 2, 2025 | Consulting Fee Vyloy · Oncology | $216 |
| Jazz Pharmaceuticals Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $3,354 |
| Incyte Corporation Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $1,720 |
| Astellas Pharma US Inc Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Nov 10, 2025 | Travel and Lodging Vyloy · Oncology · travel to El Paso, TX | $154 |
| Astellas Pharma US Inc Nov 10, 2025 | Travel and Lodging Vyloy · Oncology · travel to El Paso, TX | $40.31 |
| Incyte Corporation Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $3,440 |
| Astellas Pharma US Inc Nov 4, 2025 | Consulting Fee Vyloy · Oncology | $413 |
| Astellas Pharma US Inc Oct 20, 2025 | Travel and Lodging Vyloy · Oncology · travel to Gilbert, AZ | $464 |
| Incyte Corporation Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $1,290 |
| Astellas Pharma US Inc Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Sep 29, 2025 | Travel and Lodging Vyloy · Oncology · travel to Tucson, AZ | $529 |
| Astellas Pharma US Inc Sep 29, 2025 | Travel and Lodging Vyloy · Oncology · travel to Tucson, AZ | $137 |
| Astellas Pharma US Inc Sep 29, 2025 | Travel and Lodging Vyloy · Oncology · travel to Tucson, AZ | $40.31 |
| Jazz Pharmaceuticals Inc. Sep 23, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $2,795 |
| Incyte Corporation Sep 10, 2025 | Travel and Lodging Zynyz · Oncology · travel to Houston, TX | $599 |
| Incyte Corporation Sep 10, 2025 | Travel and Lodging Zynyz · Oncology · travel to Houston, TX | $515 |
| Incyte Corporation Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $2,580 |
| Incyte Corporation Aug 27, 2025 | Consulting Fee Zynyz · Oncology | $2,365 |
| Incyte Corporation Aug 19, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $2,580 |
| Incyte Corporation Aug 19, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $1,290 |
| Incyte Corporation Aug 19, 2025 | Travel and Lodging Zynyz · Oncology · travel to Austin, TX | $578 |
| Incyte Corporation Aug 19, 2025 | Travel and Lodging Zynyz · Oncology · travel to Austin, TX | $368 |
| Astellas Pharma US Inc Aug 18, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Aug 18, 2025 | Travel and Lodging Vyloy · Oncology · travel to Beverly Hills, CA | $552 |
| Astellas Pharma US Inc Aug 18, 2025 | Travel and Lodging Vyloy · Oncology · travel to Beverly Hills, CA | $291 |
| Astellas Pharma US Inc Aug 18, 2025 | Travel and Lodging Vyloy · Oncology · travel to Beverly Hills, CA | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. Aug 14, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · ONCOLOGY | $1,020 |
| AstraZeneca Pharmaceuticals LP Aug 8, 2025 | Consulting Fee IMFINZI · Oncology | $1,005 |
| Incyte Corporation Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $1,720 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · ONCOLOGY | $1,530 |
| Astellas Pharma US Inc Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Jul 28, 2025 | Travel and Lodging Vyloy · Oncology · travel to Las Vegas, NV | $735 |
| Astellas Pharma US Inc Jul 28, 2025 | Travel and Lodging Vyloy · Oncology · travel to Las Vegas, NV | $397 |
| Astellas Pharma US Inc Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $275 |
| Incyte Corporation Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $3,655 |
| Incyte Corporation Jun 21, 2025 | Travel and Lodging Zynyz · Oncology · travel to Chicago, IL | $535 |
| Incyte Corporation Jun 21, 2025 | Travel and Lodging Zynyz · Oncology · travel to Chicago, IL | $204 |
| Incyte Corporation Jun 21, 2025 | Travel and Lodging Zynyz · Oncology · travel to Chicago, IL | $96.43 |
| Incyte Corporation Jun 20, 2025 | Travel and Lodging Zynyz · Oncology · travel to Chicago, IL | $206 |
| Incyte Corporation May 29, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $215 |
| Takeda Pharmaceuticals U.S.A., Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · ONCOLOGY | $2,550 |
| Astellas Pharma US Inc Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,300 |
| Astellas Pharma US Inc Apr 21, 2025 | Travel and Lodging Vyloy · Oncology · travel to Oklahoma City, OK | $837 |
| Astellas Pharma US Inc Apr 21, 2025 | Travel and Lodging Vyloy · Oncology · travel to Oklahoma City, OK | $149 |
| Astellas Pharma US Inc Apr 21, 2025 | Travel and Lodging Vyloy · Oncology · travel to Oklahoma City, OK | $60.06 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · ONCOLOGY | $3,570 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · ONCOLOGY | $3,570 |
| Astellas Pharma US Inc Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,300 |
| Astellas Pharma US Inc Mar 10, 2025 | Travel and Lodging Vyloy · Oncology · travel to Tyler, TX | $814 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 5, 2025 | Travel and Lodging FRUZAQLA · ONCOLOGY · travel to ABILENE, TX · in-kind | $1,205 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 26, 2025 | Travel and Lodging FRUZAQLA · ONCOLOGY · travel to HOUSTON, TX · in-kind | $78.56 |
| Jazz Pharmaceuticals Inc. Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $1,957 |
| Astellas Pharma US Inc Feb 8, 2025 | Consulting Fee Vyloy · Oncology | $550 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 7, 2025 | Travel and Lodging FRUZAQLA · ONCOLOGY · travel to HOUSTON, TX · in-kind | $559 |
| Astellas Pharma US Inc Feb 3, 2025 | Travel and Lodging Vyloy · Oncology · travel to Oklahoma City, OK | $837 |
| Astellas Pharma US Inc Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) Vyloy · Oncology | $3,850 |
| Astellas Pharma US Inc Jan 27, 2025 | Travel and Lodging Vyloy · Oncology · travel to Albuquerque, NM | $146 |
| Astellas Pharma US Inc Jan 27, 2025 | Travel and Lodging Vyloy · Oncology · travel to Albuquerque, NM | $70.34 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $123,375 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer.
Jazz Pharmaceuticals Inc. - A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC
Genentech, Inc. - M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatoce…
AbbVie Inc. - Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
Genentech, Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.